Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Treatment of chronic inflammatory demyelinating polyneuropathy

Abstract

The management of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the main topic of this review. A few comments will also be made about treatment of the demyelinating form of paraproteinaemic demyelinating polyneuropathy (PDN) and of multifocal motor neuropathy (MMN). The review briefly describes the main characteristics of these neuropathies, and examines case series and trials which evaluated the principal therapeutic strategies for CIDP, PDN and MMN, such as intravenous immunoglobulin (IVIg) therapy, steroid treatment, plasma exchange and immunosuppressor administration. Controlled trials demonstrated that IVIg, steroid treatment and plasma exchange are effective in CIDP. For PDN the therapeutic strategies are the same as for idiopathic CIDP, but usually the clinical response is poorer. For MMN, IVIg therapy is definitely the first choice treatment.

Sommario

Lo scopo principale di questa review è di esaminare le strategie terapeutiche nella neuropatia infiammatoria cronica demielineizzante (CIDP). Alcuni commenti vengono fatti anche riguardo il trattamento della forma demielinizzante della neuropatia demielinizzante paraproteinemica (PDN) e della neuropatia motoria multifocale (MMN). La review delinea le principali caratteristiche cliniche delle diverse forme di neuropatia demielinizzante ed esamina i principali studi clinici, controllati e non controllati, che hanno valutato il trattamento deila CIDP e della PDN e MMN con immunoglobuline endovena (IVIg), con la terapia steroidea, la plasmaferesi e farmaci immunosoppressori. Studi controllati hanno dimostrato che le IVIg, to steroide e la plasmaferesi sono efficaci nella CIDP. Per quanto riguarda la PDN le strategic terapeutiche sono analoghe a quelle adottate nella CIDP anche se la risposta clinica è solitamente meno evidente. Infine, nella MMN le IVIg sono sicuramente il trattamento di prima scelta.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Hartung HP, Reiners K, Toyka KV, Pollard JD (1994) Giullain-Barrè syndrome and CIDP. In: Hohlfeld R (ed) Immunological neuromuscular disorders. Kluwer, Dordrecht, pp 33–104

  2. 2.

    Prineas JW, Mcleod JG (1976) Chronic relapsing polyneuritis. J Neurol Sci 27:427–458

  3. 3.

    Koski CL, Humphrey R, Shin ML (1985). Anti-peripheral myelin antibody in patients with demyelinating neuropathy: Quantitative and kinetic determination of serum antibody by complement component I fixation. Proc Natl Acad Sci USA 82:905–909

  4. 4.

    Van Doorn PA, Brand A, Vermeulen M (1987) Clinical significance of antibodies against peripheral nerve tissue in inflammatory polyneuropathy. Neurology 37:1798–1802

  5. 5.

    Fredman P, Vedeler CA, Nyland H et al (1991) Antibodies in antisera from patients with inflammatory demyelinating poliradiculo-neuropathy react with ganglioside LM1 and sulfatide of peripheral nerve myelin. J Neurol 238:76–79

  6. 6.

    Conolly AM, Pestronk A, Trotter JL et al (1993) High titer selective serum anti β tubulin antibodies in chronic inflammatory demyelinating polyneuropathy. Neurology 43:557–562

  7. 7.

    Simone IL, Annunziata P, Maimone D (1993) Serum and CSF antibodies to ganglioside GM1 in Guillain-Barré syndrome and chronic inflammatory polyneuropathy. J Neurol Sci 114:49–55

  8. 8.

    Saida K, Sumner AJ, Saida T (1980) Antiserum mediated demyelinization: Relationship between remyelinization and functional recovery. Ann Neurol 8:12–24

  9. 9.

    Saida T, Saida K, Lisak RP, Brown MJ et al (1982) In vivo demyelinating activity of sera from patients with Guillain-Barrè syndrome. Ann Neurol 11:69–75

  10. 10.

    Heininger K, Liebert UG, Toyka KV, Haneveld FT et al (1984) Chronic inflammatory demyelinating polyradiculoneuropathy. Reduction of nerve conduction velocities in monkeys by sistemic passive transfer of immunoglobulin G. J Neurol Sci 66:1–14

  11. 11.

    Lassmann H, Fierz W, Neuchrist C et al (1991) Chronic relapsing esperimental allergic neuritis induced by repeated transfer of P2-protein reactive T cell lines. Brain 144:429–442

  12. 12.

    Van Doorn PA, Vermeulen M, Brand A, Mulder PGH, Busch HFM (1991) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy. Clinical and laboratory characteristics associated with improvement. Arch Neurol 48:217–220

  13. 13.

    McCombe PA, Pollard JD, McLeod JG (1987) Chronic inflammatory demyelinating polyradiculoneuropathy: A clinical and electrophysiological study of 92 cases. Brain 110:1617–1630

  14. 14.

    Gorson KC, Allam G, Ropper AH (1997) Chronic inflammatory demyelinating polyneuropathy: Clinical feature and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 48:321–328

  15. 15.

    Dyck PJ, Lais AC, Ohta M et al (1975) Chronic inflammatory polyradiculoneuropathy. Mayo Clin Proc 50:621–637

  16. 16.

    Barohn RJ, Kisser JT, Warmolts JR, Mendell JR (1989) Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 46:878–884

  17. 17.

    Hughes RAC (1990) Guillain-Barrè syndrome. Springer, Berlin Heidelberg New York

  18. 18.

    Cornblath DR, Chaudry V, Griffin JW (1991) Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol 30:104–106

  19. 19.

    Dyck PJ, Prineas J, Pollard J (1993) Chronic inflammatory demyelinating polyradiculoneuropathy. In: Dyck PJ, Thomas PK, Griffin JW, Low A, Poduslo JF (eds) Peripheral neuropathy, 3rd edn. WB Saunders, Philadelphia, pp 1498–1517

  20. 20.

    Ad Hoc Subcommittee of the American Academy of Neurology (1991) AIDS Task Force: Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 41:617–618

  21. 21.

    Albers J, Kelly J (1989) Aquired inflammatory demyelinating polyneuropathies: Clinical and electrodiagnostic features. Muscle Nerve 12:435

  22. 22.

    Simmons Z, Albers JW, Bromberg MB, Feldman EL (1995) Long term follow-up of patients with chronic inflammatory demyelinating polyneuropathy without and with monoclonal gammopathy. Brain 118:359–368

  23. 23.

    Nevo Y, Pestronk A, Kornberg AJ, Connolly AM et al (1996) Childhood chronic inflammatory demyelinating neuropathies: Clinical course and long term follow-up. Neurology 47:98–102

  24. 24.

    Austin JH (1958) Recurrent polyneuropathies and their corticosteroid treatment. With five-year observation of a placebocontrolled case treated with corticotropin, cortisone, and prednisone. Brain 81:157–192

  25. 25.

    Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD et al (1982) Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 11:136–141

  26. 26.

    DeVivo DC, Engel WK (1970) Remarkable recovery of steroid-positive recurrent polyneuropathy. J Neurol Neurosurg Psychiatry 33:62–69

  27. 27.

    Levy RL, Newkirk R, Ochoa J (1979) Treating chronic relapsing Guillain-Barrè syndrome by plasma exchange (letter). Lancet 2:259–260

  28. 28.

    Server AC, Lefkowith J, Braine H, McKhann GM (1979) Treatment of chronic relapsing inflammatory polyradiculoneuropathy by plasma exchange. Ann Neurol 6:258–261

  29. 29.

    Toyka KV, Augspach R, Wietholter H, Besinger UA et al (1982) Plasma exchange in chronic inflammatory polyneuropathy: Evidence suggestive of pathogenic humoral factor. Muscle Nerve 5:479–484

  30. 30.

    Dyck PJ, Daube J, O'Brien P et al (1986) Plasma exchange in chronic inflammatory demyelinating polyneuropathy. N Engl J Med 314:461–465

  31. 31.

    Hahn AF, Bolton CF, Pillay N, Chalk C et al (1996) Plasmaexchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind sham controlled cross-over study. Brain 119:1055–1066

  32. 32.

    Heininger K, Gibbels K, Besinger UA, Borberg H et al (1990) Role of therapeutic plasmapheresis in chronic inflammatory demyelinating polyradiculoneuropathy. In: Rock G (ed) Apheresis. Wiley-Liss, New York, pp 275–281

  33. 33.

    Thornton CA, Griggs RC (1994) Plasma exchange and intravenous immunoglobulin treatment of neuromuscular disease (review). Ann Neurol 35:260–268

  34. 34.

    Fanaroff AA, Korones SB, Wright LL et al (1994) A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network. N Engl J Med 330:1007–1013

  35. 35.

    Schwarzt SA (1993) Clinical use of immune serum globulin as replacement therapy in patients with primary immunodeficiency syndromes. Clin Rev Allergy Immunol 10:1–12

  36. 36.

    Ronda N, Hurez V, Kazatchine MD (1993) Intravenous immunoglobulin therapy of autoimmune and systemic inflammatory diseases. Vox Sang 65:65–72

  37. 37.

    Sullivan KM, Kopecky KJ, Jocom J et al (1990) Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation N Engl J Med 323:705–712

  38. 38.

    Huang-Xuan K, Leger JM, Younes-Chennoufi B et al (1993) Traitment des neuropathies dusimmunitaires par immunoglobulines polyvalents intraveineuses. Rev Neural 149:385–392

  39. 39.

    Faed JM, Day B, Pollock M, Taylor PK, Nukada H, Hammond-Tooke GD (1989) High-dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology 39:422–425

  40. 40.

    Hodkinson SJ, Pollard JD, McLeod JG (1990) Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 53:327–330

  41. 41.

    Nemni R, Fazio S, Fazio R, Galardi G, Previtali S, Comi G (1994) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating neuropathy not responsive to other treatments. J Neurol Neurosurg Psychiatry 57(Suppl):43–45

  42. 42.

    Vermeulen M, Van Doorn PA, Brand A, Strengers PFW, Jennekens FGI, Busch HFM (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: A double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56:36–39

  43. 43.

    Dyck PJ, Litchy WJ, Kratz KM et al (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838–845

  44. 44.

    Hahn AF, Bolton CF, Pillay N, Chalk C et al (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo controlled, cross-over study. Brain 119:1067–1077

  45. 45.

    Kahn SN, Riches PG, Kohn J (1980) Paraproteinemia in neurological disease: Incidence, associations, and classification of monoclonal immunoglobulins. J Clin Pathol 33:617–621

  46. 46.

    Kelly JJ, Kyle RA, O'Brien PC, Dyck PJ (1981) Prevalence of monoclonal protein in peripheral neuropathy. Neurology 31:1480–1483

  47. 47.

    Krol V, Straaten MJ, Ackerstaff RG, DeMaat CE (1985) Peripheral polyneuropathy and monoclonal gammopathy of undetermined significance. J Neurol Neurosurg Psychiatry 48(7):706–708

  48. 48.

    Osby E, Noting L, Hast R, Kjellin KG, Knutsson E, Siden A (1982) Benign monoclonal gammopathy and peripheral neuropathy. Br J Haematol 51(4):531–539

  49. 49.

    Vrethem M, Cruz M, Huang W, Malm C, Holmgren H, Ernerudh J (1993) Clinical, neurophysiological and immunological evidence of polyneuropathy in patients with monoclonal gammopathies. J Neurol Sci 114:193–199

  50. 50.

    Nobile-Orazio E, Manfredini E, Carpo M et al (1994) Frequency and clinical correlates of anti-neural IgM antibodies in neuropathy associated with IgM monoclonal gammopathy. Ann Neurol 36:416–424

  51. 51.

    Dalakas MC, Engel WK (1981) Polyneuropathy with monoclonal gammopathy: Studies of 11 patients. Ann Neurol 10:45–52

  52. 52.

    Kelly JJ, Adelman E, Berkman E, Bhan I (1988) Polyneuropathies associated with IgM monoclonal gammopathies. Arch Neurol 45:1355–1359

  53. 53.

    Yeung KB, Thomas PK, King RHM et al (1991) The clinical spectrum of peripheral neuropathies associated with benign monoclonal IgM, IgG and IgA paraproteinaemia. Comparative clinical, immunological and nerve biopsy findings. J Neurol 238:383–391

  54. 54.

    Nobile-Orazio E, Baldini L, Barbieri S et al (1988) Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol 24:93–97

  55. 55.

    Waterston JA, Brown MM, Ingram DA, Swash M (1992) Cyclosporin A therapy in paraprotein-associated neuropathy. Muscle Nerve 15:445–448

  56. 56.

    Dellagi K, Chedru F, Clauvel JP, Brouet JC (1984) Neuropathie periphédrique de la macroglobulinemie de Waldenstrom. Presse Med 13:1199–1201

  57. 57.

    Sherman WH, Olarte MR, McKiernan G, Sweeney K, Latov N, Hays AP (1984) Plasma exchange treatment of peripheral neuropathy associated with plasma cell dyscrasia. J Neurol Neurosurg Psychiatry 47:813–819

  58. 58.

    Simmons Z, Bromberg MB, Feldman EL, Blaivas M (1993) Polyneuropathy associated with IgA monoclonal gammopathy of undetermined significance. Muscle Nerve 16:77–83

  59. 59.

    Dyck PJ, Low PA, Windebank AJ et al (1991) Plasma exchange in polyneuropathy associated with monoclonal gammopathy of undetermined significance. N Engl J Med 325:1482–1486

  60. 60.

    Ellie E, Vital A, Steck A, Boiron JM, Vital C, Julien J (1996) Neuropathy associated with “benign” anti-myelin-associated glycoprotein IgM gammopathy: Clinical, immunological, neurophysiological, pathological findings and response to treatment in 33 cases. J Neurol 243:34–43

  61. 61.

    Oksenehendler E, Chevret S, Léger JM et al (1995) Plasma exchange and chlorambucil in polyneuropathy associated with monoclonal IgM gammopathy. J Neurol Neurosurg Psychiatry 59:243–247

  62. 62.

    Cook D, Dalakas M, Galdi A, Biondi D, Porter H (1990) High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology 40:212–214

  63. 63.

    Léger JM, Younes-Chennoufi AB, Chassande B et al (1994) Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry 57(Suppl):46–49

  64. 64.

    Notermans NC, Lokhorst HM, Frassen H, Van Der Graaf Y, Teunissen LL, Jennekens FG, Van Den Berg LH, Wokke JH (1996) Neurology 47(5):1227–1233

  65. 65.

    Blume G, Pestronk A, Goodnough LT (1995) Anti-MAG antibody-associated polyneuropathies: Improvement following immunotherapy with monthly plasma-exchange and IV cyclophosphamide. Neurology 45(8):1577–1180

  66. 66.

    Kaji R, Hirota N, Oka N et al (1994) Anti-GM1 antibodies and impaired blood-nerve barrier may interfere with remyelination in multifocal motor neuropathy. Muscle Nerve 17:108–110

  67. 67.

    Corse AM, Chaudry V, Crawford TO, Cornblath D, Kuncl R, Griffin J (1996) Sensory nerve pathology in multifocal motor neuropathy. Ann Neurol 39:319–325

  68. 68.

    Lange DJ, Trojaborg W, Latov N, Hays AP, Younger DS, Uncini A, Blake DM, Hirano M, Burns SM, Lovelace RE et al (1992) Multifocal motor neuropathy with conduction block: Is it a distinct clinical entity? Neurology 43(3 Pt 1):497–505

  69. 69.

    Kornberg AJ, Pestronk A (1994) The clinical and diagnostic role of anti-GMI antibody testing. Muscle Nerve 17(1):100–104

  70. 70.

    Feldman EL, Bromberg MB, Alberts JW, Pestronk A (1991) Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol 30:397–401

  71. 71.

    Krarup C, Stewart JD, Sumner AJ, Pestronk A, Lipton SA (1990) A syndrome of asymmetric limb weakness with motor conduction block. Neurology 40:118–127

  72. 72.

    Parry GJ, Clarke S (1988) Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve 11:103–107

  73. 73.

    Pestronk A, Cornblath DR, Ilyas AA et al (1988) A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 24:73–78

  74. 74.

    Donaghy M, Mills KR, Boniface SJ, Simmons J, Wright I, Gregson N, Jacobs J (1994) Pure motor demyelinating neuropathy: Deterioration after steroid treatment and improvement with intravenous immunoglobulin J Neurol Neurosurg Psychiatry 57(7):778–783

  75. 75.

    Van Den Berg LH, Lokhorst H, Wokke JH (1997) Neurology 48(4):1135

  76. 76.

    Bouche P, Moulonguet A, Younes-Chennoufi AB et al (1995) Multifocal motor neuropathy with conduction block: A study of 24 patients. J Neurol Neurosurg Psychiatry 59:38–44

  77. 77.

    Chaudry V, Corse AM, Cornblath DR et al (1993) Multifocal motor neuropathy: Response to human immune globulin. Ann Neurol 33:237–242

  78. 78.

    Comi G, Amadio S, Galardi G, Fazio R, Nemni R (1944) Clinical and neurophysiological assessment of immunoglobulin therapy in five patients with multifocal motor neuropathy. J Neurol Neurosurg Psychiatry 57(Suppl):35–37

  79. 79.

    Kaji R, Shibasaki H, Kimura J (1992) Multifocal demyelinating motor neuropathy: Cranial nerve involvement and immunoglobulin therapy. Neurology 42:506–509

  80. 80.

    Nobile-Orazio E, Meucci N, Barbieri S, Carpo M, Scarlato G (1993) High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology 43:537–544

  81. 81.

    Parry GJ (1996) AAEM case report # 30: Multifocal motor neuropathy. Muscle Nerve 19:269–276

  82. 82.

    Azulay JP, Blin O, Pouget J et al (1994) Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: A double-blind, placebo-controlled study. Neurology 44:429–432

  83. 83.

    Van Den Berg LH, Kerkoff H, Oey PL et al (1995) Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: A double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59:248–252

  84. 84.

    Azulay JP, Rihet P, Pouget J, Cador F, Blin O, Boucraut J, Serratrice G (1997) Long term follow up of multifocal motor neuropathy with conduction block under treatment. J Neurol Neurosurg Psychiatry 62(4):391–394

Download references

Author information

Correspondence to G. Comi.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Comi, G., Roveri, L. Treatment of chronic inflammatory demyelinating polyneuropathy. Ital J Neuro Sci 19, 261–269 (1998). https://doi.org/10.1007/BF00713851

Download citation

Key words

  • Chronic inflammatory demyelinating polyneuropathy
  • Immunoglobulins
  • Corticosteroids
  • Plasma exchange
  • Monoclonal gammopathy
  • Multifocal motor neuropathy